Related Experiment Videos
[Tuberculosis among HIV-infected persons in Norway]
1Infeksjonsmedisinsk avdeling Medisinsk divisjon Ullevål sykehus 0407 Oslo. vidar.ormaasen@ioks.uio.no
Summary
Treating concurrent tuberculosis and HIV infection is complex due to drug interactions. Early evaluation and treatment of latent tuberculosis in HIV-infected individuals are crucial for preventing active disease.
Area of Science:
- Infectious Diseases
- Immunology
- Public Health
Context:
- HIV-infected individuals face a significantly higher risk of active tuberculosis.
- Tuberculosis is a unique opportunistic infection in HIV patients posing a public health risk.
- Managing co-infection requires careful consideration of drug interactions.
Purpose:
- To review current literature and clinical experience regarding the management of concurrent HIV and tuberculosis.
- To outline treatment strategies and drug regimens for co-infected patients.
- To emphasize the importance of screening for tuberculosis in all HIV-infected individuals.
Summary:
- Treatment options for co-infected patients are limited by drug interactions between anti-tuberculosis drugs (rifamycins) and antiretrovirals (protease inhibitors, non-nucleoside analogues).
- A suggested first-line regimen involves rifabutin with indinavir or nelfinavir for concomitant therapy.
- For patients without severe immunodeficiency, antiretroviral therapy can be deferred until after the initial tuberculosis treatment phase.
Impact:
- Effective management strategies are essential to improve outcomes for patients with HIV and tuberculosis co-infection.
- Proactive treatment of latent tuberculosis infection can prevent the development of active disease in HIV-positive individuals.
- Universal screening for tuberculosis in HIV-infected populations is recommended to facilitate timely diagnosis and treatment.